Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) and Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Adaptive Biotechnologies and Brainstorm Cell Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adaptive Biotechnologies | 0 | 1 | 4 | 0 | 2.80 |
| Brainstorm Cell Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Adaptive Biotechnologies currently has a consensus target price of $9.10, indicating a potential upside of 9.24%. Brainstorm Cell Therapeutics has a consensus target price of $30.00, indicating a potential upside of 1,566.67%. Given Brainstorm Cell Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Adaptive Biotechnologies.
Risk & Volatility
Institutional & Insider Ownership
99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 6.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 6.7% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Adaptive Biotechnologies and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adaptive Biotechnologies | -89.12% | -64.65% | -26.45% |
| Brainstorm Cell Therapeutics | N/A | N/A | -528.56% |
Valuation and Earnings
This table compares Adaptive Biotechnologies and Brainstorm Cell Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adaptive Biotechnologies | $178.96 million | 6.87 | -$159.49 million | ($1.09) | -7.64 |
| Brainstorm Cell Therapeutics | N/A | N/A | -$17.19 million | ($4.80) | -0.38 |
Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Brainstorm Cell Therapeutics beats Adaptive Biotechnologies on 7 of the 13 factors compared between the two stocks.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
